Published in Pharma Investments, Ventures and Law Weekly, July 25th, 2004
The CHMP has recommended to the European Commission that approval be granted for pemetrexed. If approved, this cancer therapy will be marketed throughout the European Union by Lilly under the brand name Alimta (pemetrexed). Marketing authorization by the European Commission is expected later this year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly